Cannabis dispensary operator Fine Fettle is converting its remaining recreational-only shops in Connecticut to hybrid models, allowing medical cannabis patients to purchase products at all nine locations starting this week. This move addresses a sharp decline in the state's medical program and aims to boost patient access amid shifting market dynamics.
Expansion Details and Operational Shifts
Fine Fettle's shops in Manchester, Norwalk, Old Saybrook, Waterbury, and West Hartford—previously recreational-only—now join existing hybrid stores in Bristol, Newington, Stamford, and Willimantic. The transition required significant investments, including private consultation spaces, staff retraining, remote verification systems, and expanded inventory for medical needs.
- Key upgrades: Rethought scheduling, recreated menus, multiple inspections.
- Pharmacist changes: On-site for one eight-hour shift weekly, with telehealth otherwise.
Chief Operating Officer Ben Zachs emphasized that lower margins for medical sales are offset by expected customer growth and loyalty, as hybrid access meets a critical patient need.
Declining Medical Program and Market Pressures
Since recreational sales launched in early 2023, Connecticut's registered medical cannabis patients have plummeted from nearly 49,000 to under 32,000. Total cannabis revenue dipped in 2025 to $290 million from $293 million in 2024, with untaxed medical sales dropping $21 million despite recreational gains of $17.5 million.
Experts note patients letting registrations lapse often bypass local recreational markets for neighboring states like New York or Massachusetts, where higher-potency products abound, or unregulated sources such as online vapes and gas station hemp items. These alternatives pose health risks due to inconsistent quality and potency, underscoring the value of trusted hybrid dispensaries.
Legislative Enablers and Broader Implications
June 2025 legislation streamlined conversions by waiving lotteries for hybrid licenses and easing pharmacist mandates, enabling operators like Fine Fettle to expand without cutting staff. Connecticut Cannabis Ombudsman Erin Gorman Kirk welcomes the change, predicting shorter travel for patients and potential retention in the medical program.
This shift reflects a national trend where mature cannabis markets blend medical and recreational to sustain revenues and patient care. By prioritizing service for chronic conditions—where precise dosing and vetted products matter—Fine Fettle positions itself to recapture lapsed patients, stabilize state revenues, and counter interstate competition. Long-term, it could model improved public health outcomes through better access and education.
